Bare Financial Services
PTGX icon

Bare Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Bare Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.6K Buy
203
+17
+9% +$2.42K 0.01% 174
2026
Q2 		$22.8K Buy
186
+91
+96% +$9.5K 0.01% 229
2026
Q1 		$10K Sell
95
-15
-14% -$1.33K ﹤0.01% 344
2025
Q4 		$9.6K Buy
110
+76
+224% +$6.22K ﹤0.01% 260
2025
Q3 		$2.26K Buy
34
+11
+48% +$625 ﹤0.01% 783
2025
Q2 		$1.27K Buy
+23
New +$1.1K ﹤0.01% 843

Other funds holding PTGX

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Bare Financial Services's PTGX Position: Q3 2026 in Review

Bare Financial Services increased its Protagonist Therapeutics (PTGX) stake by 9.1% in Q3 2026, buying an estimated $2.42K and bringing the position to 203 shares worth $28.6K. The position accounts for 0.01% of the portfolio, ranked #174.

Bare Financial Services first reported a position in PTGX in Q2 2025 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Bare Financial Services held 203 shares of Protagonist Therapeutics worth $28.6K as of Q3 2026.
  • Bare Financial Services bought 17 Protagonist Therapeutics shares in Q3 2026, an estimated $2.42K.
  • Protagonist Therapeutics made up 0.01% of Bare Financial Services's portfolio in Q3 2026, its #174 holding.
  • Bare Financial Services first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.